Provectus (NASDAQ: PVCT) CEO updates Form 4 to correct Series D-1 preferred holdings

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing filed an updated Form 4 that corrects a past reporting error rather than recording a new transaction. The filing adjusts his reported holdings of Series D-1 Convertible Preferred Stock, with the footnote stating the change "does not reflect a transaction."

After this correction, Pershing is shown holding 2,866,761 shares of Series D-1 Convertible Preferred Stock. Each preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under the certificate of designation terms.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Convertible Preferred Stock	45,860	$0.00	--

Holdings After Transaction: Series D-1 Convertible Preferred Stock — 2,866,761 shares (Direct, null)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.

Key Figures

Adjusted Series D-1 preferred grant entry: 45,860 shares Underlying common shares for adjusted entry: 458,600 shares Series D-1 preferred held after adjustment: 2,866,761 shares +2 more

5 metrics

Adjusted Series D-1 preferred grant entry 45,860 shares Series D-1 Convertible Preferred Stock entry tied to correction

Underlying common shares for adjusted entry 458,600 shares Common Stock underlying 45,860 Series D-1 preferred shares

Series D-1 preferred held after adjustment 2,866,761 shares Total Series D-1 Convertible Preferred Stock following correction

Conversion ratio 10 common shares per preferred Each Series D-1 preferred share converts into 10 common shares

Automatic conversion date December 31, 2028 Series D-1 preferred automatic conversion into common stock

Key Terms

Series D-1 Convertible Preferred Stock, Common Stock, Certificate of Designation, automatic conversion, +1 more

5 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares"

Common Stock financial

"convertible into 10 shares of the Issuer's common stock, par value $0.001"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Certificate of Designation regulatory

"in accordance with the terms of the Certificate of Designation for the Series D-1"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

automatic conversion financial

"will automatically convert into Common Stock on December 31, 2028"

par value financial

"Issuer's common stock, par value $0.001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 12:39 PM Accepted by SEC EDGAR 07/02/2026 - 12:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Convertible Preferred Stock	(1)	06/30/2026		A		45,860		06/30/2026	(2)	Common Stock	458,600	$0	2,866,761(3)	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.

	/s/ Ed Pershing	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edward Pershing report in this PVCT Form 4 filing?

The Form 4 updates Edward Pershing’s holdings to correct a past typo. A footnote explains the reported amount adjusts a typographical error in a previously filed Form 4 and does not represent a new transaction or change in economic ownership.

Does this PVCT Form 4 show Edward Pershing buying or selling shares?

No, the filing explicitly states it does not reflect a transaction. The adjustment corrects a typographical error in an earlier Form 4, so there is no new purchase, sale, or other economic change for Edward Pershing in this report.

How many Series D-1 preferred shares does Edward Pershing hold after the correction at PVCT?

After the correction, Pershing is reported holding 2,866,761 Series D-1 preferred shares. This figure comes from the total shares following the adjustment, reflecting his updated ownership of the Series D-1 Convertible Preferred Stock class.

How many PVCT common shares are underlying Pershing’s new Series D-1 grant entry?

The updated entry relates to 45,860 Series D-1 preferred shares, convertible into 458,600 common shares. Each Series D-1 share is convertible into 10 common shares, as described in the footnote explaining the security’s conversion ratio.

When will PVCT’s Series D-1 Convertible Preferred Stock automatically convert to common stock?

The Series D-1 preferred stock automatically converts on December 31, 2028. A footnote states it will convert into common stock on that date unless it is converted earlier in line with the Series D-1 certificate of designation terms.

What is the conversion ratio for PVCT’s Series D-1 Convertible Preferred Stock?

Each Series D-1 preferred share converts into 10 common shares. The footnotes specify that every share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus Biopharmaceuticals common stock with a stated par value of $0.001 per share.